Why listen
The FDA rejected MDMA therapy for trauma, and the reasons why are more troubling than the decision itself.
0:00––:––
Enjoy the episode?
Subscribe to The Psychedelic Report
Listen & subscribe on
In this episode
- What the FDA rejection means for veterans and trauma patients seeking treatment
- How one organization allegedly falsified information to block MDMA therapy approval
- A former insider exposes serious ethical violations and questions about funding
- What advocates and patients are doing to keep the path to approval open
About this episode
In this episode, Dr. Dave Rabin discusses the impact of the FDA's decision, the potential delays in accessing this crucial treatment, and the unethical behavior of certain organizations influencing the FDA. Dr. Rabin is joined by Jon Lubecky, a retired army sergeant and Veteran who took part in MAPS MDMA therapy trials, as he discusses the implications of this rejection and emphasizes the need for ongoing advocacy and hope for eventual approval. The episode also addresses the unethical behavior of Symposia, an organization accused of falsifying information to the FDA to obstruct MDMA therapy approval. Additionally, former Symposia member David Nichols reveals serious ethical violations within the organization, raising questions about their motives and funding. Through these discussions, the episode highlights the critical need for transparency, ethical practices, and continued efforts to ensure access to psychedelic treatments for those in need.Rachel Nuwer’s Scientific American Article: https://www.scientificamerican.com/article/fdas-rejection-of-mdma-psychotherapy-for-trauma-draws-criticism-from/
Jon Lubecky’s Conversation with David Nickles on Breaking Points: https://www.youtube.com/watch?v=lttFB0c0cAo
- Web: https://psychedelic.support/
- Twitter: https://twitter.com/DrDavidRabin
- Instagram: https://www.instagram.com/drdavidrabin
- Web: https://www.drdave.io/
Learn more about your ad choices. Visit megaphone.fm/adchoices
About The Psychedelic Report
Dr. Dave Rabin MD, PhD, a psychiatrist and neuroscientist trained in Ketamine and MDMA-assisted therapy, brings you the newest developments from the world of psychedelic science and technology. From researchers and investors to physicians and shamans to nonprofit pioneers and policy-makers — each week, Dr.
See all episodes →
